Sagimet Biosciences Inc. Price & Performance (SGMT)

Sagimet Biosciences has begun Phase 3 trials for its lead drug, denifanstat, targeting metabolic dysfunction-associated steatohepatitis (MASH). The program follows FDA Breakthrough Therapy designation, signaling regulatory confidence in the drug's potential. With $158.7 million in cash reserves, the company is positioned to fund operations well into 2025.12

HC Wainwright has raised its earnings estimates for Sagimet Biosciences, citing improved quarterly performance. The firm now predicts a Q1 2025 loss of $1.00 per share, up from $1.08. Analysts maintain a "Buy" rating with a $32 price target, reflecting optimism in the company’s pipeline and financial strategy.34

Sagimet Biosciences received FDA clearance for its second fatty acid synthase inhibitor, TVB-3567, aimed at treating acne. The drug targets sebum production, addressing a core cause of acne. With clinical trials set to begin in 2025, this development diversifies Sagimet’s portfolio and reduces its reliance on a single asset.56